247 related articles for article (PubMed ID: 28094768)
1. BCL-W has a fundamental role in B cell survival and lymphomagenesis.
Adams CM; Kim AS; Mitra R; Choi JK; Gong JZ; Eischen CM
J Clin Invest; 2017 Feb; 127(2):635-650. PubMed ID: 28094768
[TBL] [Abstract][Full Text] [Related]
2. BCL-W makes only minor contributions to MYC-driven lymphoma development.
Diepstraten ST; La Marca JE; Chang C; Young S; Strasser A; Kelly GL
Oncogene; 2023 Sep; 42(37):2776-2781. PubMed ID: 37567974
[TBL] [Abstract][Full Text] [Related]
3. Myc suppression of Nfkb2 accelerates lymphomagenesis.
Keller U; Huber J; Nilsson JA; Fallahi M; Hall MA; Peschel C; Cleveland JL
BMC Cancer; 2010 Jul; 10():348. PubMed ID: 20598117
[TBL] [Abstract][Full Text] [Related]
4. Targeting lysosomal degradation induces p53-dependent cell death and prevents cancer in mouse models of lymphomagenesis.
Maclean KH; Dorsey FC; Cleveland JL; Kastan MB
J Clin Invest; 2008 Jan; 118(1):79-88. PubMed ID: 18097482
[TBL] [Abstract][Full Text] [Related]
5. Endogenous Bcl-xL is essential for Myc-driven lymphomagenesis in mice.
Kelly PN; Grabow S; Delbridge AR; Strasser A; Adams JM
Blood; 2011 Dec; 118(24):6380-6. PubMed ID: 21998213
[TBL] [Abstract][Full Text] [Related]
6. A dual role for the anti-apoptotic Bcl-2 protein in cancer: mitochondria versus endoplasmic reticulum.
Akl H; Vervloessem T; Kiviluoto S; Bittremieux M; Parys JB; De Smedt H; Bultynck G
Biochim Biophys Acta; 2014 Oct; 1843(10):2240-52. PubMed ID: 24768714
[TBL] [Abstract][Full Text] [Related]
7. BCL-W is dispensable for the sustained survival of select Burkitt lymphoma and diffuse large B-cell lymphoma cell lines.
Diepstraten ST; Chang C; Tai L; Gong JN; Lan P; Dowell AC; Taylor GS; Strasser A; Kelly GL
Blood Adv; 2020 Jan; 4(2):356-366. PubMed ID: 31985804
[TBL] [Abstract][Full Text] [Related]
8. Activating and sustaining c-Myc by depletion of miR-144/451 gene locus contributes to B-lymphomagenesis.
Ding L; Zhang Y; Han L; Fu L; Mei X; Wang J; Itkow J; Elabid AEI; Pang L; Yu D
Oncogene; 2018 Mar; 37(10):1293-1307. PubMed ID: 29284789
[TBL] [Abstract][Full Text] [Related]
9. [Molecular genetic features of sporadic Burkitt's lymphoma in children].
Yang WP; Huang H; Gong LP; Wu Y; Xu HY; Zou Y; Lü BB; Zhong HS; Deng QQ; Xiao Q; Zeng ST; Zhu CD
Zhonghua Bing Li Xue Za Zhi; 2010 Dec; 39(12):819-24. PubMed ID: 21215097
[TBL] [Abstract][Full Text] [Related]
10. Comparative immunohistochemical analysis of pediatric Burkitt lymphoma and diffuse large B-cell lymphoma.
Frost M; Newell J; Lones MA; Tripp SR; Cairo MS; Perkins SL
Am J Clin Pathol; 2004 Mar; 121(3):384-92. PubMed ID: 15023043
[TBL] [Abstract][Full Text] [Related]
11. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants.
Hemann MT; Bric A; Teruya-Feldstein J; Herbst A; Nilsson JA; Cordon-Cardo C; Cleveland JL; Tansey WP; Lowe SW
Nature; 2005 Aug; 436(7052):807-11. PubMed ID: 16094360
[TBL] [Abstract][Full Text] [Related]
12. Synergy between PI3K signaling and MYC in Burkitt lymphomagenesis.
Sander S; Calado DP; Srinivasan L; Köchert K; Zhang B; Rosolowski M; Rodig SJ; Holzmann K; Stilgenbauer S; Siebert R; Bullinger L; Rajewsky K
Cancer Cell; 2012 Aug; 22(2):167-79. PubMed ID: 22897848
[TBL] [Abstract][Full Text] [Related]
13. Development of a real-time reverse transcription polymerase chain reaction assay for c-myc expression that allows the identification of a subset of c-myc+ diffuse large B-cell lymphoma.
Sáez AI; Artiga MJ; Romero C; Rodríguez S; Cigudosa JC; Pérez-Rosado A; Fernández I; Sánchez-Beato M; Sánchez E; Mollejo M; Piris MA
Lab Invest; 2003 Feb; 83(2):143-52. PubMed ID: 12594230
[TBL] [Abstract][Full Text] [Related]
14. The distinction between Burkitt lymphoma and diffuse large B-Cell lymphoma with c-myc rearrangement.
Nakamura N; Nakamine H; Tamaru J; Nakamura S; Yoshino T; Ohshima K; Abe M
Mod Pathol; 2002 Jul; 15(7):771-6. PubMed ID: 12118116
[TBL] [Abstract][Full Text] [Related]
15. Molecular classification of MYC-driven B-cell lymphomas by targeted gene expression profiling of fixed biopsy specimens.
Carey CD; Gusenleitner D; Chapuy B; Kovach AE; Kluk MJ; Sun HH; Crossland RE; Bacon CM; Rand V; Dal Cin P; Le LP; Neuberg D; Sohani AR; Shipp MA; Monti S; Rodig SJ
J Mol Diagn; 2015 Jan; 17(1):19-30. PubMed ID: 25468432
[TBL] [Abstract][Full Text] [Related]
16. Noncanonical regulation of the Hedgehog mediator GLI1 by c-MYC in Burkitt lymphoma.
Yoon JW; Gallant M; Lamm ML; Iannaccone S; Vieux KF; Proytcheva M; Hyjek E; Iannaccone P; Walterhouse D
Mol Cancer Res; 2013 Jun; 11(6):604-15. PubMed ID: 23525267
[TBL] [Abstract][Full Text] [Related]
17. The IKK2/NF-{kappa}B pathway suppresses MYC-induced lymphomagenesis.
Klapproth K; Sander S; Marinkovic D; Baumann B; Wirth T
Blood; 2009 Sep; 114(12):2448-58. PubMed ID: 19628709
[TBL] [Abstract][Full Text] [Related]
18. Burkitt lymphoma is immunophenotypically different from Burkitt-like lymphoma in young persons.
Hutchison RE; Finch C; Kepner J; Fuller C; Bowman P; Link M; Schwenn M; Laver J; Desai S; Barrett D; Murphy SB
Ann Oncol; 2000; 11 Suppl 1():35-8. PubMed ID: 10707776
[TBL] [Abstract][Full Text] [Related]
19. Id2 is dispensable for myc-induced lymphomagenesis.
Nilsson JA; Nilsson LM; Keller U; Yokota Y; Boyd K; Cleveland JL
Cancer Res; 2004 Oct; 64(20):7296-301. PubMed ID: 15492249
[TBL] [Abstract][Full Text] [Related]
20. Bcl-2 is a better therapeutic target than c-Myc, but attacking both could be a more effective treatment strategy for B-cell lymphoma with concurrent Bcl-2 and c-Myc overexpression.
Sasaki N; Kuroda J; Nagoshi H; Yamamoto M; Kobayashi S; Tsutsumi Y; Kobayashi T; Shimura Y; Matsumoto Y; Taki T; Nishida K; Horiike S; Akao Y; Taniwaki M
Exp Hematol; 2011 Aug; 39(8):817-28.e1. PubMed ID: 21640157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
